Develops injectable drugs for subcutaneous delivery of biologics.
Jun 2026Revenue $1.66B/yrExpenses $1.07B/yr
No trend
Figures by year
Is Halozyme Therapeutics profitable?
Yes. In the 12 months to Jun 2026, revenue was $1.66B and expenses $1.07B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.40B | $928M | $469M |
| Dec 2024 | $1.02B | $464M | $551M |
| Dec 2023 | $829M | $492M | $338M |
| Dec 2022 | $660M | $393M | $268M |
| Dec 2021 | $443M | $167M | $276M |
| Dec 2020 | $268M | $123M | $144M |
| Dec 2019 | $196M | $264M | −$67.6M |
| Dec 2018 | $152M | $221M | −$69.3M |
| Dec 2017 | $317M | $236M | $81.0M |
| Dec 2016 | $147M | $230M | −$83.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.